News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Moleculin Biotech (MBRX) Announces FDA Orphan Drug Designation for its Brain Tumor Drug


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This drug is a new class called "immune transduction modifiers" and targets 3 important markers: STAT3, HIF1-a and c-Myc as well as JAK2..  Will keep an eye on this one. There is a clinical trial in Texas:   https://clinicaltrials.gov/ct2/show/NCT01904123


Posted on: 02/05/2019

Moleculin Biotech (MBRX) Announces FDA Orphan Drug Designation for its Brain Tumor Drug

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740